List of Excipients in Branded Drug MACITENTAN

« Back to Dashboard

Generic Drugs Containing MACITENTAN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	macitentan	0378-0606	GLYCERYL MONO- AND DICAPRYLOCAPRATE
Mylan Pharmaceuticals Inc	macitentan	0378-0606	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	macitentan	0378-0606	MICROCRYSTALLINE CELLULOSE 101
Mylan Pharmaceuticals Inc	macitentan	0378-0606	POLYSORBATE 80

What are the Most Frequently-Used Excipients in MACITENTAN?

# Of NDCs	Excipient
8	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
2	CROSPOVIDONE
1	GLYCERYL MONO- AND DICAPRYLOCAPRATE

Macitentan Excipient Strategy and Commercial Opportunities

Last updated: October 15, 2026

Macitentan is a low-dose, once-daily endothelin receptor antagonist marketed as Opsumit for pulmonary arterial hypertension. Its commercial formulation uses conventional tablet excipients rather than a proprietary delivery platform. The strongest excipient opportunities are therefore in generic development, bioequivalent low-dose tablets, alternate oral dosage forms, regional reformulation, and supply-chain qualification rather than in a novel excipient-based life-cycle product.

The reference product is a 10 mg film-coated tablet. Its formulation supports direct compression or closely related conventional solid-dose manufacturing, with lactose, microcrystalline cellulose, sodium starch glycolate, povidone, and magnesium stearate in the tablet core. The film coating contains polyvinyl alcohol, titanium dioxide, talc, lecithin, and xanthan gum, according to the U.S. prescribing information.[1]

What is the current macitentan formulation strategy?

Macitentan is formulated as a conventional immediate-release film-coated tablet administered once daily, with or without food.[1] The reference formulation prioritizes manufacturability, content uniformity, disintegration, and stable dissolution rather than modified release.

Formulation attribute	Opsumit reference product
Active ingredient	Macitentan
Strength	10 mg
Dosage form	Film-coated tablet
Route	Oral
Frequency	Once daily
Food administration	With or without food
Primary indication	Pulmonary arterial hypertension
Core excipients	Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate
Coating excipients	Polyvinyl alcohol, titanium dioxide, talc, lecithin, xanthan gum
Original sponsor	Actelion Pharmaceuticals
Current commercial group	Johnson & Johnson through Janssen-related operations

The low 10 mg dose creates a content-uniformity challenge. The active pharmaceutical ingredient represents a relatively small share of total tablet mass, making powder blending, segregation control, API particle-size control, and sampling strategy important development variables.

Which excipients are most important for macitentan tablets?

Lactose monohydrate and microcrystalline cellulose

Lactose monohydrate provides bulk and contributes to tabletability. Microcrystalline cellulose improves compactibility and helps produce mechanically robust tablets at low drug loading.

A generic manufacturer can substitute grades of lactose or microcrystalline cellulose, but the substitution must preserve:

• Powder flow during die filling
• Blend uniformity
• Tablet tensile strength
• Disintegration time
• Dissolution across pH conditions
• Stability under humidity exposure

Direct compression grades may reduce processing steps, but they can also increase sensitivity to particle-size distribution and lubricant overmixing.

Sodium starch glycolate

Sodium starch glycolate is the principal superdisintegrant identified in the reference tablet core.[1] It supports rapid tablet breakup and helps offset the potential impact of hydrophobic lubrication from magnesium stearate.

The commercial opportunity is not simply to maximize disintegrant concentration. Excessive swelling can produce inconsistent dissolution or tablet defects. Development teams should evaluate grade, substitution level, granulation history, and compression force together.

Povidone

Povidone functions primarily as a binder and can improve granule strength and blend cohesion. Its use is relevant if a manufacturer selects wet granulation rather than direct compression.

Povidone grade and molecular weight can affect viscosity, drying behavior, residual moisture, and tablet disintegration. A generic formulation using a different povidone grade may remain pharmaceutically equivalent, but it requires comparative dissolution and stability evidence.

Magnesium stearate

Magnesium stearate improves ejection and reduces tooling friction. Overlubrication can lower tablet tensile strength and slow wetting or dissolution.

For macitentan, lubricant optimization is commercially relevant because the formulation must balance low-dose uniformity with rapid release. Shorter lubrication time, controlled shear, and tighter endpoint monitoring can improve batch consistency without changing the excipient class.

Film-coating system

The Opsumit coating uses polyvinyl alcohol, titanium dioxide, talc, lecithin, and xanthan gum.[1] The coating provides appearance, handling protection, swallowability, and potentially limited moisture protection.

A generic manufacturer can use an equivalent coating system, including commercially supplied polyvinyl alcohol-based premixes. The coating should not materially alter dissolution, tablet mass, mechanical integrity, or long-term stability.

What technical barriers affect generic macitentan development?

The main technical barriers are low-dose uniformity, dissolution reproducibility, and control of API-excipient interactions.

Low-dose blend uniformity

At 10 mg, small variations in API distribution can affect assay and content uniformity. The highest-value process controls include:

1. API particle-size and morphology characterization.
2. Ordered mixing or carrier-assisted blending where needed.
3. Segregation studies during transfer and hopper discharge.
4. In-process blend sampling based on statistically defensible locations.
5. Compression monitoring for tablet weight and hardness.

The use of finer API particles can improve distribution but may worsen cohesion, electrostatic charging, and flow. Coarser API may improve flow while increasing segregation risk.

Dissolution control

Macitentan formulation development should test dissolution across multiple media, including physiologically relevant pH conditions. The goal is not only to match a single reference profile but to demonstrate robust performance across manufacturing variability.

Critical variables include:

• Sodium starch glycolate level
• Magnesium stearate concentration and mixing time
• Tablet hardness
• Coating weight gain
• API particle size
• Granulation endpoint
• Storage humidity

Stability and packaging

A conventional blister or bottle package may be adequate, but the choice depends on moisture sensitivity, regional climate, and commercial distribution. High-humidity markets may favor aluminum-aluminum blisters or high-barrier bottles with desiccant.

Excipient suppliers can create value through:

• Low-moisture lactose grades
• Direct-compression cellulose
• Consistent superdisintegrant particle-size distributions
• Low-peroxide povidone
• Controlled-porosity coating systems
• Supply agreements with dual manufacturing sites

What patent and exclusivity issues affect macitentan excipient opportunities?

Macitentan’s market protection has multiple layers: the original chemical and use patents, regulatory exclusivity, formulation or dosage-form claims, and possible pediatric or combination-product rights. The exact live patent estate should be determined from the current FDA Orange Book, Patent and Exclusivity Search, USPTO records, and applicable court dockets.[2,3]

Regulatory exclusivity

The FDA approved Opsumit in October 2013 for pulmonary arterial hypertension.[1] New chemical entity exclusivity generally runs for five years from approval, subject to statutory exceptions. Orphan-drug exclusivity can provide seven years for the designated indication. These periods are separate from patent terms and do not necessarily expire on the same date.

Orange Book and Paragraph IV exposure

Macitentan tablets may be subject to Orange Book-listed patents covering the active ingredient, treatment methods, or approved product characteristics. A generic applicant seeking an ANDA may file:

• Paragraph I certification if no patent is listed
• Paragraph II if the patent has expired
• Paragraph III if the applicant will wait for patent expiry
• Paragraph IV if the applicant asserts that the patent is invalid, unenforceable, or not infringed

A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.[2]

The commercial significance for excipient suppliers is direct. A generic developer may complete formulation work before resolving patent risk, but launch timing depends on litigation, settlement terms, patent expiry, and regulatory approval.

Formulation and method-of-use patents

The relevant risk categories include:

Patent category	Potential relevance to excipient strategy
Composition-of-matter claims	Can delay all conventional macitentan products
Tablet or formulation claims	May affect excipient selection or process design
Method-of-use claims	Can affect labeling and indication-specific launch
Combination therapy claims	May create follow-on opportunities or additional barriers
Pediatric dosage-form claims	May affect liquid, sprinkle, or dispersible products
Manufacturing claims	May constrain API or finished-dose process design

An excipient change does not avoid a composition-of-matter patent. It may, however, help design around a narrower formulation claim if the alternative formulation is technically and legally distinct.

What FDA regulatory pathway applies to generic macitentan?

A conventional generic macitentan tablet would generally use the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the listed drug, together with appropriate chemistry, manufacturing, and controls data.[2]

Potential alternate products would follow different routes:

Product concept	Likely regulatory route
10 mg generic film-coated tablet	ANDA
Lower-strength tablet	ANDA if permitted by reference-product framework, otherwise additional development
Oral suspension	505(b)(2) or other applicable pathway
Orally disintegrating tablet	505(b)(2) or ANDA depending on equivalence
Sprinkle capsule or granules	505(b)(2) or ANDA
Fixed-dose combination	505(b)(2) or new drug application
Pediatric formulation	505(b)(2), supplemental application, or pediatric development program

FDA guidance emphasizes that excipient differences are acceptable in generic products when the formulation meets relevant regulatory requirements and does not compromise equivalence, safety, quality, or performance.[4]

What commercial opportunities exist for macitentan excipients?

Generic tablet supply

The largest near-term opportunity is supply to generic tablet manufacturers. The formulation uses high-volume, widely available excipient classes, so price competition will be significant. Differentiation will depend on quality, documentation, delivery reliability, and process performance.

The most attractive supplier packages combine:

• Direct-compression lactose
• High-functionality microcrystalline cellulose
• Consistent sodium starch glycolate
• Low-peroxide povidone
• Pharmaceutical-grade magnesium stearate
• Ready-to-use film-coating systems

Regional manufacturing

Macitentan is commercially relevant in markets with established pulmonary hypertension treatment and in countries where generic substitution is expanding. Regional manufacturers may prefer locally sourced excipients to reduce import exposure and working capital.

Suppliers with local regulatory support can compete through:

• DMF or equivalent documentation
• Pharmacopoeial compliance
• Local technical service
• Stability data in climatic zones III and IV
• Dual-site supply qualification
• Smaller minimum order quantities

Alternate oral dosage forms

The reference product is a tablet, but pulmonary arterial hypertension patients may include children, older adults, and patients with swallowing difficulties. A dispersible tablet, oral granule, oral suspension, or orally disintegrating tablet could address administration barriers.

These products face greater development risk because changes in particle size, wetting agents, suspending agents, sweeteners, or preservatives may affect exposure and palatability. They also create a stronger 505(b)(2) case than a conventional generic tablet.

Potential excipient classes include:

• Crospovidone or alternative superdisintegrants
• Poloxamers or surfactants for wetting
• Suspending agents such as xanthan gum or hydroxypropyl cellulose
• Buffer systems for pH control
• Taste-masking polymers
• High-barrier packaging systems

Fixed-dose combinations

Macitentan is used in treatment strategies that may include phosphodiesterase-5 inhibitors and prostacyclin-pathway therapies. A fixed-dose macitentan combination could reduce pill burden, but it would require compatibility, dose-ratio, clinical, and regulatory work.

The leading technical issue is matching dissolution and stability profiles for multiple active ingredients. A bilayer tablet, multiparticulate system, or separate coated granules may be needed if the APIs have incompatible processing or degradation characteristics.

How strong is the macitentan formulation patent estate?

The reference product does not depend on an obviously complex delivery technology. That reduces the technical barrier to generic formulation but does not eliminate legal risk. The strongest patent risk would normally arise from active-ingredient, method-of-treatment, or specifically claimed formulation patents rather than from the routine use of lactose, cellulose, povidone, disintegrant, and lubricant.

A practical strength assessment is:

Estate element	Strategic assessment
Conventional 10 mg tablet	Technically accessible to generic developers
Low-dose content uniformity	Moderate process-development barrier
Standard excipient system	Low differentiation and low formulation complexity
Alternate oral dosage forms	Higher technical and regulatory barrier
Method-of-use patents	Potential launch-label and litigation risk
Combination products	Separate regulatory and patent exposure
Manufacturing patents	Relevant mainly to API and specialized processes

No specific generic challenger, Paragraph IV settlement, or current litigation outcome should be treated as established without checking the live Orange Book and federal court records. Commercial planning should model both an at-risk launch scenario and a post-patent launch scenario.

How does macitentan compare with other pulmonary hypertension products?

Macitentan competes with other endothelin receptor antagonists and combination regimens, including bosentan, ambrisentan, tadalafil, sildenafil, and newer combination products.

Product	Class	Common formulation opportunity
Macitentan	Endothelin receptor antagonist	Generic 10 mg tablet, pediatric or dispersible form
Ambrisentan	Endothelin receptor antagonist	Generic tablet and combination strategy
Bosentan	Endothelin receptor antagonist	Tablet and dispersible formulations
Tadalafil	PDE-5 inhibitor	Generic tablet, combination therapy
Sildenafil	PDE-5 inhibitor	Tablet, oral suspension, pediatric use

Macitentan’s once-daily dosing and conventional tablet architecture support generic competition. Its use in chronic, specialist-managed disease also supports demand for reliable supply and patient-friendly dosage forms.

What revenue exposure does macitentan create?

Macitentan is one of the commercially important products in the pulmonary arterial hypertension market. Johnson & Johnson reports Opsumit sales within its pharmaceutical business, while Actelion originally developed and commercialized the product before its acquisition by Johnson & Johnson.[5,6]

Revenue exposure is concentrated in:

• Continued branded use before broad generic entry
• Specialist prescribing in pulmonary hypertension centers
• Combination therapy with other PAH medicines
• Geographic reimbursement and tender access
• The timing of generic approval and launch
• Any authorized generic or settlement arrangement

For excipient companies, the opportunity is less dependent on retaining branded volume than on winning platform status with multiple generic manufacturers. A supplier that qualifies its excipient system with one major ANDA sponsor may gain repeat demand across strengths, markets, and alternate dosage forms.

Key Takeaways

• Macitentan is marketed as a 10 mg once-daily immediate-release film-coated tablet.
• The reference product uses conventional excipients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate, and a polyvinyl alcohol-based coating.[1]
• The main technical challenge is low-dose content uniformity, not complex drug delivery.
• Generic manufacturers can likely compete with standard excipient systems, but process control and dissolution matching remain important.
• The highest-value excipient opportunities are direct-compression grades, low-moisture materials, robust superdisintegrants, low-peroxide binders, and high-barrier packaging.
• Pediatric, dispersible, orally disintegrating, suspension, and combination products offer greater differentiation but face higher regulatory and formulation risk.
• Patent and Paragraph IV exposure must be assessed using current Orange Book listings, FDA records, USPTO data, and litigation dockets.
• Supplier success will depend on regulatory documentation, global availability, technical support, and qualification with multiple generic manufacturers.

FAQs About Macitentan Excipient and Commercial Strategy

Can lactose be replaced in a generic macitentan tablet?

Yes. Lactose can potentially be replaced with mannitol, dibasic calcium phosphate, or another suitable filler, but the replacement must preserve tabletability, dissolution, stability, and content uniformity.

Is a liquid macitentan formulation commercially attractive?

A liquid formulation could address swallowing and pediatric-use needs, but it would require suspension stability, dose-uniformity, palatability, preservative, packaging, and regulatory development beyond a standard ANDA tablet.

Which excipient is most important for macitentan dissolution?

Sodium starch glycolate is a key disintegrant, but dissolution also depends on magnesium stearate level, lubrication time, compression force, API particle size, and coating weight.

Could an orally disintegrating macitentan tablet avoid existing patents?

Not automatically. A new dosage form may avoid some narrow formulation claims, but composition-of-matter, method-of-use, or broader product claims could still apply.

Are specialty excipients required for macitentan?

No specialty excipient is required by the reference product. Standard pharmaceutical excipients are used, creating a relatively accessible formulation platform for generic manufacturers.

References

1. U.S. Food and Drug Administration. (2023). Opsumit (macitentan) tablets, for oral use: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Patent and Trademark Office. (2024). Patent Center and patent term adjustment information.
4. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly purified synthetic peptides.
5. Johnson & Johnson. (2024). Annual report and pharmaceutical product sales disclosures.
6. European Medicines Agency. (2024). Opsumit: European public assessment report.